Table 1.
Patient characteristics
| Variable | Value |
|---|---|
| Age at transplantation, y | 36.2 (14-58, 0.23-74) |
| Sex | |
| Male | 115 (60) |
| Female | 77 (40) |
| Indication | |
| Benign | 68 (35) |
| Leukemia/lymphoma | 71 (37) |
| MDS | 30 (16) |
| Plasma cell disorder | 23 (12) |
| Cell source | |
| PB: Full graft | 24 (12) |
| Cord blood | 65 (34) |
| Bone marrow | 16 (8.3) |
| PB: α-β depleted | 87 (45) |
| Human leukocyte antigen disparity* | |
| Matched | 150 (78) |
| Mismatched | 42 (22) |
| Conditioning | |
| Samples per patient | 10 (8-12, 3-19) |
| Flu AUCt0−∞, mg*h/L | 24 (20-29, 10-66) |
| Busulfan AUCt0−∞, mg*h/L | 96.1 (90-100, 59†-120) |
| Serotherapy | |
| Patients without ATG | 20 (10) |
| Patients with ATG | 172 (90) |
| AUCTx−∞ of patients with ATG | 14.5 (2.5-38, 0-270) |
| Creatinine clearance, mL/min/1.73 m2 | 114 (94-130, 25-140) |
| Median follow-up (95% CI), d | 639 (482-758) |
Categorical variables are displayed as n (%). Continuous variables are displayed as median (interquartile range, range).
ATG, antithymocyte globulin; MDS, myelodysplastic syndrome; PB, peripheral blood.
*
In peripheral blood HCT, 90 were 10/10, 09/10, 16 were 8/8, 3 were 6/6. In cord blood HCT, 4 were 10/10, 4 were 9/10, 3 were 8/10, 21 were 6/6, 24 were 5/6, 9 were 4/6. In bone marrow HCT, all were matched 10/10.
†
Minima exclude Fanconi anemia patients (n = 3): for these patients, indication-specific myeloablation was achieved with AUCt0−∞ of 31, 31, and 25 mg*h/L.